LOXL2 and breast carcinoma: These findings are further supported by clinical data demonstrating that increases in LOXL2 mRNA levels correlate with increases in epithelial to mesenchymal transition and stem cells markers, and LOXL2 expression is also associated with a decrease in relapse-free survival of breast cancer patients [107].